179 related articles for article (PubMed ID: 33473344)
1. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
[TBL] [Abstract][Full Text] [Related]
2. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
3. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
[TBL] [Abstract][Full Text] [Related]
4. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ
Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716
[TBL] [Abstract][Full Text] [Related]
6. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
7. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
[TBL] [Abstract][Full Text] [Related]
8. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
Sardh E; Harper P; Andersson DE; Floderus Y
Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
[TBL] [Abstract][Full Text] [Related]
9. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
10. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
[TBL] [Abstract][Full Text] [Related]
11. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
Aarsand AK; Petersen PH; Sandberg S
Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
[TBL] [Abstract][Full Text] [Related]
13. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
14. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
[TBL] [Abstract][Full Text] [Related]
16. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry.
Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490
[TBL] [Abstract][Full Text] [Related]
17. Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
Lissing M; Wester A; Vassiliou D; Floderus Y; Harper P; Sardh E; Wahlin S
J Inherit Metab Dis; 2023 Nov; 46(6):1186-1194. PubMed ID: 37650859
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
[TBL] [Abstract][Full Text] [Related]
19. Acute intermittent porphyria in childhood: a population-based study.
Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
